Lawrence S Honig

List of Publications by Year
in descending order

83	8,886	159525 30	88593 70
papers	citations	h-index	g-index

93	93	93	12231
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
2	Trial of Solanezumab for Mild Dementia Due to Alzheimerâ€™s Disease. New England Journal of Medicine, 2018, 378, 321-330.	13.9	795
3	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
4	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurology, The, 2012, 11, 241-249.	4.9	390
5	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
6	Model-guided microarray implicates the retromer complex in Alzheimer's disease. Annals of Neurology, 2005, 58, 909-919.	2.8	362
7	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
8	Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and AÎ² accumulation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7327-7332.	3.3	230
9	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
10	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
11	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	15.2	182
12	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	1.4	178
13	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
14	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
15	Plasma pâ€tau181, pâ€tau217, and other bloodâ€based Alzheimer's disease biomarkers in a multiâ€ethnic, community study. Alzheimer's and Dementia, 2021, 17, 1353-1364.	0.4	160
16	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurology, The, 2019, 18, 549-558.	4.9	108
17	Role of Amyloid-Î² and Tau Proteins in Alzheimerâ€™s Disease: Confuting the Amyloid Cascade. Journal of Alzheimer's Disease, 2018, 64, S611-S631.	1.2	102
18	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97

#	Article	IF	Citations
19	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
20	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	1.2	84
21	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	1.5	78
22	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 182-192.	4.9	74
23	Heritability of telomere length in a study of long-lived families. Neurobiology of Aging, 2015, 36, 2785-2790.	1.5	61
24	Mediterranean diet and leukocyte telomere length in a multi-ethnic elderly population. Age, 2015, 37, 24.	3.0	61
25	PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology, 2015, 84, 972-980.	1.5	48
26	Frequency of GBA Variants in Autopsyâ€proven Multiple System Atrophy. Movement Disorders Clinical Practice, 2017, 4, 574-581.	0.8	47
27	A Pathological Perspective on the Natural History of Cerebral Atherosclerosis. International Journal of Stroke, 2015, 10, 1074-1080.	2.9	42
28	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
29	Soluble amyloid beta levels are elevated in the white matter of Alzheimerâ€™s patients, independent of cortical plaque severity. Acta Neuropathologica Communications, 2014, 2, 83.	2.4	39
30	Age and Sex Distributions of Ageâ€Related Biomarker Values in Healthy Older Adults from the Long Life Family Study. Journal of the American Geriatrics Society, 2016, 64, e189-e194.	1.3	38
31	Tau and other proteins found in Alzheimerâ€™s disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. Science Translational Medicine, 2020, 12, .	5.8	37
32	Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimerâ€™s Disease Treated with Escalating Doses for up to 133ÂWeeks. Journal of Alzheimer's Disease, 2020, 76, 967-979.	1.2	36
33	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	0.9	35
34	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
35	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	4.4	33
36	Alzheimer's-related changes in non-demented essential tremor patients vs. controls: Links between tau and tremor?. Parkinsonism and Related Disorders, 2014, 20, 655-658.	1.1	31

#	Article	IF	Citations
37	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
38	Determinants of cerebrovascular remodeling: Do large brain arteries accommodate stenosis?. Atherosclerosis, 2014, 235, 371-379.	0.4	27
39	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
40	Telomere length is longer in women with late maternal age. Menopause, 2017, 24, 497-501.	0.8	25
41	Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 80, 1051-1065.	1.2	25
42	Absence of C9ORF72 expanded or intermediate repeats in autopsyâ€confirmed Parkinson's disease. Movement Disorders, 2014, 29, 827-830.	2.2	24
43	Clinical Experience with Cerebrospinal Fluid AÎ²42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. Journal of Alzheimer's Disease, 2018, 65, 1417-1425.	1.2	23
44	Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs. Genome Biology, 2020, 21, 153.	3.8	23
45	Wolframin is a novel regulator of tau pathology and neurodegeneration. Acta Neuropathologica, 2022, 143, 547-569.	3.9	22
46	Predicting Cognitive Improvement in Normal Pressure Hydrocephalus Patients Using Preoperative Neuropsychological Testing and Cerebrospinal Fluid Biomarkers. Neurosurgery, 2019, 85, E662-E669.	0.6	19
47	Short telomere length is associated with renal impairment in Japanese subjects with cardiovascular risk. PLoS ONE, 2017, 12, e0176138.	1.1	16
48	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimerâ€™s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. Journal of Alzheimer's Disease, 2018, 64, 689-707.	1.2	15
49	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
50	Hippocampal Laminar Distribution of Tau Relates to Alzheimer's Disease and Age of Onset. Journal of Alzheimer's Disease, 2014, 43, 315-324.	1.2	12
51	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
52	Patterns of tau pathology identified with 18 Fâ€MKâ€6240 PET imaging. Alzheimer's and Dementia, 2021, , .	0.4	12
53	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
54	Treatment of Alzheimerâ€™s Disease: Current Management and Experimental Therapeutics. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 174-181.	0.7	11

#	Article	IF	Citations
55	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032-1033.	4.9	11
56	Low tobacco-related cancer incidence in offspring of long-lived siblings: a comparison with Danish national cancer registry data. Annals of Epidemiology, 2015, 25, 569-574.e3.	0.9	9
57	Lewy Body Dementia Associationâ€™s Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research and Therapy, 2019, 11, 23.	3.0	9
58	Pathological correlates of brain arterial calcifications. Cardiovascular Pathology, 2019, 38, 7-13.	0.7	8
59	Gene Therapy in Alzheimer Diseaseâ€”It May Be Feasible, but Will It Be Beneficial?. JAMA Neurology, 2018, 75, 791.	4.5	7
60	Leukocyte Telomere Length Is Unrelated to Cognitive Performance Among Non-Demented and Demented Persons: An Examination of Long Life Family Study Participants. Journal of the International Neuropsychological Society, 2020, 26, 906-917.	1.2	6
61	Anterolateral entorhinal cortex volume is associated with memory retention in clinically unimpaired older adults. Neurobiology of Aging, 2021, 98, 134-145.	1.5	5
62	Cerebrospinal fluid amyloid levels are associated with delayed memory retention in cognitively normal biomarker-negative older adults. Neurobiology of Aging, 2019, 84, 90-97.	1.5	4
63	Overview of dominantly inherited AD and topâ€line DIANâ€TU results of solanezumab and gantenerumab. Alzheimer's and Dementia, 2020, 16, e041129.	0.4	4
64	Solanezumab inâ€depth outcomes. Alzheimer's and Dementia, 2020, 16, e038028.	0.4	3
65	Avoid or Embrace? Practice Effects in Alzheimerâ€™s Disease Prevention Trials. Frontiers in Aging Neuroscience, 0, 14, .	1.7	3
66	P3-342: MEDITERRANEAN DIET AND LEUKOCYTE TELOMERE LENGTH IN A MULTI-ETHNIC ELDERLY POPULATION. , 2014, 10, P755-P755.		2
67	Subacute Imbalance in a Renal Transplant Patient. JAMA Neurology, 2015, 72, 1367.	4.5	2
68	Gantenerumab inâ€depth outcomes. Alzheimer's and Dementia, 2020, 16, e038049.	0.4	2
69	Amyloid and tau PET in sporadic earlyâ€onset Alzheimerâ€™s disease: Preliminary results from LEADS. Alzheimer's and Dementia, 2020, 16, e041613.	0.4	2
70	Sexâ€associated differences in pathology burden in earlyâ€onset Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e046532.	0.4	2
71	Personality Change and Gait Dysfunction. JAMA Neurology, 2015, 72, 597.	4.5	1
72	Abstract T P419: Pathological Arterial Wall Correlates of Lumen-based Remodeling: Results From the Brain Arterial Remodeling Study. Stroke, 2015, 46, .	1.0	1

#	Article	IF	Citations
73	O4-10-02: PLASMA AB40 AND AB42 DECLINE WITH PROGRESSION OF DEMENTIA. , 2014, 10, P271-P271.		0
74	JAMA NeurologyClinical Challenge. JAMA Neurology, 2015, 72, 745.	4.5	0
75	O4-04-04: Pooled biomarker analyses of phase 2 studies of vanutide cridificar vaccine (ACC-001) in mild-to-moderate and early Alzheimer's disease. , 2015, 11, P276-P277.		0
76	P3â€145: TELOMERE LENGTH IN HUMAN LEUKOCYTE SUBPOPULATIONS. Alzheimer's and Dementia, 2018, 14, P1123.	0.4	0
77	P4â€073: IN ABSENCE OF DEMENTIA, COGNITIVE PERFORMANCE DOES NOT RELATE TO THE BIOMARKER OF LEUKOCYTE TELOMERE LENGTH: AN EXAMINATION OF LONG LIFE FAMILY STUDY PARTICIPANTS. Alzheimer's and Dementia, 2018, 14, P1462.	0.4	0
78	O5â€03â€04: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE. Alzheimer's and Dementia, 2018, 14, P1646.	0.4	0
79	ICâ€Pâ€011: DOES ACQUISITION TIME AFFECT THE RESULTS OF 18Fâ€FLORBETABEN IMAGING?. Alzheimer's and Dementia, 2019, 15, P20.	0.4	0
80	Increased white matter MRI T1 hypointensity volume in youngâ€onset Alzheimerâ€™s disease patients is not accounted for by age or cardiovascular risk factors. Alzheimer's and Dementia, 2020, 16, e045577.	0.4	0
81	Plasma biomarkers AÎ²42, AÎ²40, and tau in Down syndrome dementia. Alzheimer's and Dementia, 2020, 16, e045698.	0.4	0
82	Neurodegeneration in the Longitudinal Evaluation of Early Onset Alzheimerâ€™s Disease Study (LEADS) sample: Results from the MRI core. Alzheimer's and Dementia, 2020, 16, e046338.	0.4	0
83	Association of Leukocyte Telomere Length With Perceived Physical Fatigability. Innovation in Aging, 2021, 5, 206-206.	0.0	0